Trial intelligence / Profile preview

ABT-122 in Active Psoriatic Arthritis

NCT02349451Phase 2Completed

Sponsor
AbbVie Inc.
Start
Apr 2015
Primary completion
Jul 2016
Modality
Bispecific Antibodies
01

Overview

A Phase 2 trial of remtolumab in psoriatic arthritis (PsA), sponsored by AbbVie Inc.. Started Apr 2015; status: completed.

02

Drugs

remtolumab
03

Conditions

psoriatic arthritis (PsA)

Beyond the preview

Go deeper on NCT02349451.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02349451.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call